J 2024

Advancements in risk stratification and management strategies in primary cardiovascular prevention

BARKAS, Fotios, Yusuf Ziya SENER, Pelin Arabacilar GOLFOROUSH, Azin KHEIRKHAH, Elena RODRIGUEZ-SANCHEZ et. al.

Basic information

Original name

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Authors

BARKAS, Fotios, Yusuf Ziya SENER, Pelin Arabacilar GOLFOROUSH, Azin KHEIRKHAH, Elena RODRIGUEZ-SANCHEZ, Jan NOVÁK (203 Czech Republic, belonging to the institution), Maria APELLANIZ-RUIZ, Ralph Kwame AKYEA, Vanessa BIANCONI, Alexandr CEASOVSCHIH, Ying Jie CHEE, Mariia CHERSKA, Joana Rita CHORA, Mario ORIA, Nadiia DEMIKHOVA, Duygu Kocyigit BURUNKAYA, Antoine RIMBERT, Chiara MACCHI, Krishnaraj RATHOD, Lynn ROTH, Vasily SUKHORUKOV, Svetlana STOICA, Roberto SCICALI, Tatyana STOROZHENKO, Jamol UZOKOV, Maria Giovanna LUPO, Emiel P C VAN DER VORST and Florentina PORSCH

Edition

Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2024, 0021-9150

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.300 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.atherosclerosis.2024.117579

UT WoS

001250139600001

Keywords in English

Cardiovascular disease; Atherosclerosis; Risk stratification; Plaque regression; Primary prevention

Tags

14110116, 14110515, rivok

Tags

International impact, Reviewed
Změněno: 12/7/2024 08:54, Mgr. Tereza Miškechová

Abstract

V originále

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega -3 fatty acids, antihypertensive agents, as well as glucose -lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.
Displayed: 6/11/2024 00:50